Form 10 Explorer
10-Q
Quarterly Report
AIM IMMUNOTECH INC.

AIM

NYSEAMER

CIK: 946644

File #: 001-27072

Period End: Jun 30, 2025

Fiscal Year: 2025

View on EDGAR
Balance Sheet
34 line items · 2 periods
XBRL
ItemJun 30, 2025Dec 31, 2024
ASSETS
Current assets:
Cash and Cash Equivalents
476,0001,701,000
Marketable securities
359,0002,276,000
Fair Value, Inputs, Level 1
359,0002,276,000
Other Non-Operating Current Assets
190,000199,000
Total current assets
1,025,0004,176,000
Property, Plant and Equipment
89,000108,000
Operating Lease Right-of-Use Asset
496,000618,000
Intangible Assets
2,168,0002,594,000
Patents
2,078,0002,495,000
Trademarks
90,00099,000
Other Non-Operating Non-Current Assets
351,0001,112,000
Total assets
4,129,0008,608,000
LIABILITIES AND STOCKHOLDERS’ DEFICIT
Current liabilities:
Accounts Payable
7,297,0006,383,000
Other Current Liabilities
573,000606,000
Operating Lease Liability, Current
233,000239,000
Short-Term Debt
2,290,0002,307,000
Total current liabilities
10,393,0009,535,000
Long-term liabilities:
Operating Lease Liability, Non-Current
282,000395,000
Total liabilities
10,675,0009,930,000
Stockholders’ deficit:
Total Stockholders' Equity
1,0001,000
Total Stockholders' Equity
426,780,000425,505,000
Total Stockholders' Equity
(433,327,000)(426,828,000)
Total stockholders’ deficit
(6,546,000)(1,322,000)
Common Stock
1,0001,000
Additional Paid-in Capital
426,780,000425,505,000
Retained Earnings
(433,327,000)(426,828,000)
Minimum
6,000,000
Total liabilities and stockholders’ deficit
4,129,0008,608,000